Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Oncologists Embrace BRAF Testing, Coast Through Managed Care With New Melanoma Drugs

Dec 12 2011

• By Emily Hayes

Related Content

Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?

Oct 27 2011

<i>Zelboraf</i> Approval Hastened By FDA Officials Impressed With Early Efficacy

Aug 22 2011

With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers

Aug 22 2011

Bristol Basks In Broad Ipilimumab Label, Sets High Price

Mar 25 2011

Pfizer’s <i>Xalkori</i> Joins The Six-Figure Oncology Drug Club

Sep 05 2011

NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges

May 30 2011

Front-Line Of Melanoma Market Could Be Marketing Battle

Jun 13 2011

Quality Of Biomarkers Questioned Again; Lancet Report Calls For Better Evidence

Oct 01 2011

Related Companies

Bristol Myers Squibb Company

Roche Holding AG

Merck & Co., Inc.

Pfizer Inc.

Dendreon Corporation

Additional Topics

Launches Reimbursement BioPharmaceutical Medical Device

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window